USPTO 2015–2025 USPTO PatentsView Foreign Corporation

EVOGENE LTD.

USPTO PatentsView assignee record — 103 granted patents across 8 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

103
Total patents granted
8
CPC technology areas
15.7
Avg claims per patent
+10%
5-year filing velocity

Portfolio overview

EVOGENE LTD. has been granted 103 US utility patents between 2015 and 2024, placing EVOGENE LTD. at rank #3,560 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.7 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, EVOGENE LTD. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 39.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 54 grants, compared with 49 in the 2015–2019 window — a +10% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. EVOGENE LTD.'s 15.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EVOGENE LTD. against peers pursuing similar technology classes.

How does EVOGENE compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows EVOGENE holds 103 patents — placing it at rank #3,560 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2024

05101520 2015201620172018201920202021202220232024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
EVOGENE LTD. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 7 6.8%
2016 7 6.8%
2017 10 9.7%
2018 11 10.7%
2019 14 13.6%
2020 16 15.5%
2021 14 13.6%
2022 18 17.5%
2023 5 4.9%
2024 1 1.0%

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Standard
Velocity Growing

Where it ranks

Overall rank by patents

#3,560

Across all tracked assignees

Innovation Score

39.1 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does EVOGENE LTD. hold?
EVOGENE LTD. holds 103 US granted patents filed between 2015 and 2024, spanning 8 technology areas.
What is EVOGENE LTD.'s Innovation Score?
EVOGENE LTD. has an Innovation Score of 39.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does EVOGENE LTD. focus on?
EVOGENE LTD.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 103 patents. The company has filed patents in 8 CPC subclasses total.
Is EVOGENE LTD.'s patent filing rate increasing or decreasing?
EVOGENE LTD.'s recent filing velocity is +10% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for EVOGENE LTD.'s patents?
EVOGENE LTD.'s patents average 15.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the EVOGENE LTD. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope